Evidences from meta-analyses showed that mineralocorticoid receptor antagonists (MRAs),2 sodium glucose cotransporter 2 inhibitors (SGLT2i),3 and glucagon-like peptide 1 receptor agonists (GLP-1 RA)4 have demonstrated efficacy in reducing heart failure events in patients with HFpEF. This evidence concerns the gene NR3C2 and heart failure.